Gilead drug modestly delays breast cancer progression in late-stage trial

 Gilead Sciences Inc's (GILD.O) Trodelvy extended by 1.5 months, or 34%, the length of time women with advanced stages of a common type of breast cancer lived without their disease worsening, according to trial data presented on Saturday.

https://www.reuters.com/business/healthcare-pharmaceuticals/gilead-drug-modestly-delays-breast-cancer-progression-late-stage-trial-2022-06-04/